MX2016006741A - Uso del dominio de union de una subunidad de una estructura de multiples subunidades para la liberacion dirigida de entidades farmaceuticamente activas a la estructura de multiples subunidades. - Google Patents
Uso del dominio de union de una subunidad de una estructura de multiples subunidades para la liberacion dirigida de entidades farmaceuticamente activas a la estructura de multiples subunidades.Info
- Publication number
- MX2016006741A MX2016006741A MX2016006741A MX2016006741A MX2016006741A MX 2016006741 A MX2016006741 A MX 2016006741A MX 2016006741 A MX2016006741 A MX 2016006741A MX 2016006741 A MX2016006741 A MX 2016006741A MX 2016006741 A MX2016006741 A MX 2016006741A
- Authority
- MX
- Mexico
- Prior art keywords
- subunit
- subunit structure
- targeted delivery
- binding domain
- pharmaceutically active
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8132—Plasminogen activator inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Abstract
Se reporta aquí el uso de un conjugado de una subunidad de una estructura de múltiples subunidades y una entidad biológicamente activa para la liberación dirigida de la entidad biológicamente activa a la estructura de múltiples subunidades.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13196356 | 2013-12-10 | ||
PCT/EP2014/076952 WO2015086548A1 (en) | 2013-12-10 | 2014-12-09 | Use of the binding domain of a subunit of a multi-subunit structure for targeted delivery of pharmaceutically active entities to the multi-subunit structure |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016006741A true MX2016006741A (es) | 2016-08-12 |
Family
ID=49765825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016006741A MX2016006741A (es) | 2013-12-10 | 2014-12-09 | Uso del dominio de union de una subunidad de una estructura de multiples subunidades para la liberacion dirigida de entidades farmaceuticamente activas a la estructura de multiples subunidades. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20170008949A1 (es) |
EP (1) | EP3080156A1 (es) |
JP (1) | JP2017501970A (es) |
KR (1) | KR20160089390A (es) |
CN (1) | CN105793285A (es) |
BR (1) | BR112016009617A2 (es) |
CA (1) | CA2941958A1 (es) |
MX (1) | MX2016006741A (es) |
WO (1) | WO2015086548A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019527537A (ja) * | 2016-06-07 | 2019-10-03 | マックス−デルブリュック−セントルム フュール モレキュラー メディツィン イン デア ヘルムホルツ−ゲマインシャフト | キメラ抗原受容体と、bcmaに結合するcar−t細胞 |
TWI790206B (zh) * | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至cd3和cd123的雙特異性抗體樣結合蛋白 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7057015B1 (en) * | 1999-10-20 | 2006-06-06 | The Salk Institute For Biological Studies | Hormone receptor functional dimers and methods of their use |
AUPR030900A0 (en) * | 2000-09-22 | 2000-10-12 | Queensland University Of Technology | Growth factor complex |
US7271149B2 (en) * | 2000-12-07 | 2007-09-18 | Eli Lilly And Company | GLP-1 fusion proteins |
WO2003033666A2 (en) * | 2001-10-16 | 2003-04-24 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes |
US7056683B2 (en) * | 2002-11-12 | 2006-06-06 | Massachusetts Institute Of Technology | Genetically encoded fluorescent reporters of kinase, methyltransferase, and acetyl-transferase activities |
MX2010007586A (es) * | 2008-01-09 | 2011-02-22 | Intrexon Corp | Inhibidores terapeuticos de la funcion del inhibidor del activador de plasminogeno 1 y metodos de uso. |
WO2012035034A1 (en) * | 2010-09-14 | 2012-03-22 | F. Hoffmann-La Roche Ag | Serpin-finger fusion polypeptide |
US20130280162A1 (en) * | 2010-12-22 | 2013-10-24 | Ifom Fondazione Istituto Firc Di Oncologia Molecolare | uPAR-ANTAGONISTS AND USES THEREOF |
WO2012130831A1 (en) * | 2011-03-29 | 2012-10-04 | Roche Glycart Ag | Antibody fc variants |
-
2014
- 2014-12-09 CA CA2941958A patent/CA2941958A1/en not_active Abandoned
- 2014-12-09 WO PCT/EP2014/076952 patent/WO2015086548A1/en active Application Filing
- 2014-12-09 MX MX2016006741A patent/MX2016006741A/es unknown
- 2014-12-09 EP EP14825111.9A patent/EP3080156A1/en not_active Withdrawn
- 2014-12-09 JP JP2016528813A patent/JP2017501970A/ja active Pending
- 2014-12-09 CN CN201480066672.0A patent/CN105793285A/zh active Pending
- 2014-12-09 BR BR112016009617A patent/BR112016009617A2/pt not_active IP Right Cessation
- 2014-12-09 KR KR1020167015078A patent/KR20160089390A/ko not_active Application Discontinuation
-
2016
- 2016-06-09 US US15/178,247 patent/US20170008949A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2941958A1 (en) | 2015-06-18 |
BR112016009617A2 (pt) | 2017-09-19 |
US20170008949A1 (en) | 2017-01-12 |
WO2015086548A1 (en) | 2015-06-18 |
CN105793285A (zh) | 2016-07-20 |
JP2017501970A (ja) | 2017-01-19 |
EP3080156A1 (en) | 2016-10-19 |
KR20160089390A (ko) | 2016-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1212890A1 (zh) | 生物活性分子、其偶聯物及治療用途 | |
EA201591004A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
BR112015020389A2 (pt) | compostos carbazol úteis como inibidores de bromodomínio | |
PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
CR20140567A (es) | Formulaciones y métodos para la administración vaginal de antiprogestinas | |
BR112015020453A8 (pt) | "formas de dosagem de liberação prolongada orais de tofacitinibe e uso de tofacitinibe | |
MX2015009785A (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
EA201390804A1 (ru) | Лекарственная форма лакозамида для приема один раз в сутки | |
UY34350A (es) | Derivados de pirazolquinolinona, su preparación y su uso terapéutico. | |
EA201270619A1 (ru) | Применение бетанехола для лечения ксеростомии | |
MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
EP3015116A4 (en) | Antibody-drug conjugate having improved stability and use thereof | |
BR112015030387A2 (pt) | compostos de pirazol como moduladores de fshr e usos dos mesmos | |
UA115357C2 (uk) | Похідні піридин-4-ілу | |
TWD177319S (zh) | 護膝 | |
MX2013006418A (es) | Derivados de oxazolil-metileter como agonistas del receptor de alx. | |
EA201690974A1 (ru) | Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника | |
UY34154A (es) | Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel. | |
UY34543A (es) | Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica. | |
MX2013012918A (es) | Formulaciones de liberacion sostenida de paracetamol. | |
EA201490562A1 (ru) | Способы лечения связанной с инсультом сенсорно-двигательной недостаточности с использованием аминопиридинов | |
MX2016006741A (es) | Uso del dominio de union de una subunidad de una estructura de multiples subunidades para la liberacion dirigida de entidades farmaceuticamente activas a la estructura de multiples subunidades. | |
BR112016028081A2 (pt) | Novos compostos como agentes antituberculares |